A Phase 1/2 Study of DCC-3116 as Monotherapy and Combination Therapy in Patients With MAPK Pathway Mutant Solid Tumors

  • STATUS
    Recruiting
  • End date
    Oct 16, 2024
  • participants needed
    323
  • sponsor
    Deciphera Pharmaceuticals LLC
Updated on 16 June 2022
cancer
systemic therapy
lung cancer
BRAF
KRAS
NRAS
mek inhibitor
trametinib
lung carcinoma
braf v600e mutation

Summary

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

Details
Condition Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Advanced Solid Tumor, Metastatic Solid Tumor
Treatment Trametinib, Binimetinib, Sotorasib, DCC-3116
Clinical Study IdentifierNCT04892017
SponsorDeciphera Pharmaceuticals LLC
Last Modified on16 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female participants ≥18 years of age
Dose Escalation Phase (Part 1)
Participants must have a histologically confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations
Progressed despite standard therapies, and received at least 1 prior line of anticancer therapy
Participants with a documented mutation in BRAF V600E or V600K must have received approved treatments known to provide clinical benefit prior to study entry
Participants enrolled in the DCC-3116 and sotorasib cohort (Cohort D) must have a
KRAS G12C mutation
Dose Expansion Phase (Part 2)
Received at least 1 prior line but no more than 3 prior lines of systemic therapy in the advanced or metastatic setting
Cohort 1: Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
Histologically confirmed PDAC with a documented mutation in KRAS
Received only 1 prior line of systemic therapy in the advanced or metastatic setting
Cohort 2: Patients with Non-Small Cell Lung Cancer (NSCLC)
Histologically confirmed NSCLC with a documented mutation in KRAS, NRAS, NF1, or BRAF
Received at least 2 prior lines but no more than 4 prior lines of systemic therapy in the advanced or metastatic setting
Cohort 3: Patients with Colorectal Cancer (CRC)
Histologically confirmed CRC with a documented mutation in KRAS, NRAS, NF1, or BRAF
Received 2-3 prior lines of systemic therapy in the advanced or metastatic setting
Cohort 4: Patients with Melanoma
Histologically confirmed melanoma with a documented mutation in NRAS
Must be able to provide tumor tissue sample
Received 1-2 prior lines of systemic therapy in the advanced or metastatic setting that included T-cell checkpoint inhibitor-based therapy
Have not received prior MEK inhibitor therapy
Adequate organ function and bone marrow function
Cohort 5: Patients with KRAS G12C mutant NSCLC
If a female of childbearing potential must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements
Histologically confirmed NSCLC with a documented mutation in KRAS G12C
Male participants must agree to follow contraception requirements
Must provide signed consent to participate in the study and is willing to comply with study-specific procedures
Have not received prior sotorasib or other KRAS G12C inhibitor therapy
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 (Dose Escalation) or 0 to 1 (Dose Expansion) at Screening

Exclusion Criteria

Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease Note: A participant with previously treated brain metastases may participate provided that they are stable
New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug
Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on repeated demonstration of QTcF >450 ms in males or >470 ms in females at screening, or history of long QT syndrome
Left ventricular ejection fraction (LVEF) <50% at Screening
Systemic arterial thrombotic or embolic events
Must not have received the following within the specified time periods prior to the first dose of study drug
Systemic venous thrombotic events
Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp including certain herbal medications (eg, St. John's Wort): 14 days or 5× the half-life of the medication (whichever is longer)
All other prior anticancer therapies or any therapy that is investigational for the participant's condition with a known safety and PK profile: 14 days or 5× the half-life of the medication (whichever is shorter)
Bone disease that requires treatment
Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug.-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days
Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must be healed and free of infection or dehiscence before the first dose of the study drug
Grapefruit or grapefruit juice: 14 days
Have not recovered from all toxicities from prior therapy according to National Cancer
Any other clinically significant comorbidities
Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Known human immunodeficiency virus or hepatitis C infection only if the participant is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection
If female, the participant is pregnant or lactating
Malabsorption syndrome
For participants receiving DCC-3116 and trametinib combination or DCC-3116 and binimetinib combination: previous treatment with trametinib or binimetinib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to trametinib or binimetinib
For participants receiving DCC-3116 and sotorasib combination in Dose Escalation Part
previous treatment with sotorasib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to sotorasib
For participants receiving DCC-3116 and sotorasib combination: Use of proton pump
inhibitors (PPIs) and H2 receptor antagonists that cannot be discontinued 3
days prior to the start of study drug administration
Known allergy or hypersensitivity to any component of the investigational drug products
Ongoing participation in an interventional study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note